Compositions containing HMG Co-A reductase inhibitors and policosanol

A pharmaceutical formulation for the treatment of atherosclerosis, or for the reduction of plasma cholesterol levels, and suitable for filling softgel capsules comprising:

• (a) an effective amount of an HMG-CoA reductase inhibitor;
• (b) an effective amount of a compound that inhibits cholesterol synthesis at a point between the formation of acetate and mevalonate and (c) a carrier comprising polyethylene glycol and glycerine.

A kit comprising in separate containers in a single package pharmaceutical compositions wherein said pharmaceutical compositions are combined to treat athersclerosis or to reduce plasma cholesterol levels which comprises in one container an effective amount of a cholesterol biosynthesis inhibitor selected from the group consisting of HMG CoA reductase inhibitors in a pharmaceutically acceptable carrier, and in a second container, an effective amount of compound that inhibits cholesterol synthesis at a point between the formation of acetate and mevalonate.

A method for treating a disorder related to elevated serum cholesterol concentration in a mammalian subject, comprising administering to the subject a therapeutically effective amount of a combination of a cholesterol biosynthesis inhibitor selected from the group consisting of HMG CoA reductase inhibitors and a compound that inhibits cholesterol synthesis at a point between the formation of acetate and mevalonate, wherein said combination includes (a) at least one inhibitor of HMG CoA reductase and (b) a compound that inhibits cholesterol synthesis at a point between the formation of acetate and mevalonate.

A method for treating hypercholesterolemia comprising administering to a patient:

• (a) a first effective amount of policosanol;
• and
• (b) a second effective amount of an HMG CoA reductase inhibitor.